This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2020 Jul;16(7):361-362.

doi: 10.1200/OP.20.00079.

How and When to Manage Ruxolitinib Failure in Myelofibrosis

Affiliations

PMID: 32649854
DOI: 10.1200/OP.20.00079

Comment

How and When to Manage Ruxolitinib Failure in Myelofibrosis

Ruben A Mesa. JCO Oncol Pract. 2020 Jul.

. 2020 Jul;16(7):361-362.

doi: 10.1200/OP.20.00079.

Author

Affiliation

¹ Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX.

PMID: 32649854
DOI: 10.1200/OP.20.00079

No abstract available

PubMed Disclaimer

Comment on

Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group.
Gupta V, Cerquozzi S, Foltz L, Hillis C, Devlin R, Elsawy M, Grewal K, Hamm C, McNamara C, Sirhan S, Leber B. Gupta V, et al. JCO Oncol Pract. 2020 Jul;16(7):351-359. doi: 10.1200/JOP.19.00506. Epub 2020 Mar 5. JCO Oncol Pract. 2020. PMID: 32134707 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

P30 CA054174/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information